Tranexamic acid is an antifibrinolytic agent used in a range of bleeding situations, including menorrhagia. It carries a risk of venous and arterial thrombosis (1). The magnitude of this risk has now been determined by the results of a study with long-term follow-up of several tens of thousands of female patients (2). A cohort of about 2 million women aged 15 to 49 years was established in Denmark using several healthcare databases. There were many exclusion criteria, mainly a history of hysterectomy, cancer, diabetes orthromboembolism, or use of hormone or anticoagulant therapy. Exposure to tranexamic acid was estimated from pharmacy dispensing data. Tranexamic acid was most often used for menorrhagia at a dose of 1 gthree times per day for5 days. During the period 1996-2017, the women were followed for a median duration of 5.3 years.
展开▼
